CAROLYN CANTERBURY: Open Payments
NPI 1942510102 · MONTGOMERY CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$735 in 39 payments from 13 companies in 2025. Trend: 2023 $182 · 2024 $535 · 2025 $735
Food & beverage: $735
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 10 | $182 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $120 |
| Alkermes, Inc. | 5 | $95 |
| Otsuka America Pharmaceutical, Inc. | 3 | $73 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| Aimmune Therapeutics, Inc. | 2 | $40 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Collegium Pharmaceutical, Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
Products named: INGREZZA, CAPLYTA, ARISTADA, REXULTI, FANAPT, ZENPEP, JARDIANCE, UZEDY.
Industry payments across MO — which companies pay providers there.
